Nilo Therapeutics

Visit Website

Neuro-immunology company developing medicines that harness master-regulator brain-body neural circuits, including vagal pathways, to restore immune homeostasis in autoimmune and inflammatory disease rather than broadly suppressing immunity.

Headquarters

New York City, USA

Year Founded

2024

Founders

Charles Zuker, Ruslan Medzhitov, Steve Liberles

Country

United States

Financial Information

Funding Stage

Series A

Recent Funding

$101M

Funding By

The Column Group, DCVC Bio, Lux Capital, Gates Foundation, Alexandria Venture Investments

Core Technology

Neural-circuit immunomodulation (vagal master-regulator pathways)

Product Type

Drug

Pipeline Stage (Very Important)

Preclinical

Regulatory Status

IND Filed: No
FDA/EMA Status: N/A
Clinical Trial Registration: N/A
Patents / IP Status: Building IP from Columbia / Yale / Harvard science

Partnerships

Pharma Collaborations

None disclosed

Academic / Hospital Tie-ups

Columbia University, Yale University, Harvard University

CRO/CDMO Partnerships

None disclosed

Market & Differentiation

First-in-class approach: central neural circuits to reset systemic immunity